Ontology highlight
ABSTRACT:
SUBMITTER: Berti A
PROVIDER: S-EPMC5486186 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Berti Alvise A Cavalli Giulio G Guglielmi Barbara B Biavasco Riccardo R Campochiaro Corrado C Tomelleri Alessandro A Nicoletti Roberto R Panzacchi Andrea A Ferrarini Marina M Dagna Lorenzo L
Oncoimmunology 20170420 6
Treatment of Erdheim-Chester disease (ECD), a rare non-Langerhans histiocytosis, relies on interferon-α, chemotherapeutic agents such as purine analogs, cytokine-blocking agents and BRAF inhibitors. Since interleukin (IL)-6 levels are elevated in serum and lesions of ECD patients, we evaluated the therapeutic efficacy and safety of IL-6 blockade with tocilizumab. We conducted an open-label, single-arm, phase II, prospective study of tocilizumab in three patients with multisystem ECD and poor tol ...[more]